ENLIVEN THERAPEUTICS, INC. (ELVN) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $73.00K; Additional Paid in CapitalUSD $1.30B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.91M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $61.00K; Additional Paid in CapitalUSD $824.48M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-382.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $59.00K; Additional Paid in CapitalUSD $806.37M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $334.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $59.00K; Additional Paid in CapitalUSD $793.34M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $221.00K.
ENLIVEN THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $73.00K | $1.30B | $-1.91M | $-403.28M | $895.15M | (m) | 3 month · $13.91M | (m) |
| 2026-03-31 | $0.00 | $61.00K | $824.48M | $-382.00K | $-370.79M | $453.37M | (m) | 3 month · $7.40M | (m) |
| 2025-12-31 | $0.00 | $59.00K | $806.37M | $334.00K | $-347.17M | $459.60M | (m) | 12 month · $34.02M | (m) |
| 2025-09-30 | $0.00 | $59.00K | $793.34M | $221.00K | $-317.50M | $476.12M | (m) | 3 month · $7.18M | (m) |
| 2025-06-30 | $0.00 | $59.00K | $785.94M | $-177.00K | $-297.35M | $488.47M | (m) | 3 month · $7.72M | (m) |
| 2025-03-31 | $0.00 | $49.00K | $560.28M | $-16.00K | $-272.02M | $288.30M | (m) | 3 month · $6.80M | (m) |
| 2024-12-31 | $0.00 | $49.00K | $553.21M | $55.00K | $-243.47M | $309.85M | (m) | 12 month · $20.17M | (m) |
| 2024-09-30 | $0.00 | $47.00K | $508.41M | $242.00K | $-220.29M | $288.40M | (m) | 3 month · $5.18M | (m) |
| 2024-06-30 | $0.00 | $47.00K | $502.16M | $-139.00K | $-197.14M | $304.93M | 3 month · $135.00K | 3 month · $5.14M | (m) |
| 2024-03-31 | $0.00 | $47.00K | $494.90M | $-53.00K | $-177.19M | $317.71M | (m) | 3 month · $4.51M | (m) |
| 2023-12-31 | $0.00 | $41.00K | $400.17M | $141.00K | $-154.45M | $245.91M | (m) | 12 month · $12.91M | (m) |
| 2023-09-30 | (m) | $41.00K | $396.93M | $-147.00K | $-135.08M | $261.75M | (m) | 3 month · $3.40M | (m) |
| 2023-06-30 | (m) | $41.00K | $393.37M | $-111.00K | $-114.31M | $278.99M | (m) | 3 month · $4.20M | (m) |
| 2023-03-31 | (m) | $41.00K | $388.96M | (m) | $-97.59M | $291.42M | (m) | 3 month · $2.26M | (m) |
| 2023-02-23 | (m) | $164.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $1.00K | $6.04M | $0.00 | $-82.86M | $-76.83M | (m) | 12 month · $3.19M | (m) |
| 2022-09-30 | (m) | $27.00K | $235.46M | $-4.00K | $-178.19M | $-68.10M | (m) | 3 month · $1.10M | (m) |
| 2022-06-30 | (m) | $27.00K | $234.96M | $-35.00K | $-173.59M | $-58.71M | (m) | 3 month · $701.00K | (m) |
| 2022-03-31 | (m) | $27.00K | $234.57M | $-51.00K | $-162.14M | $-50.61M | (m) | 3 month · $654.00K | (m) |
| 2021-12-31 | (m) | $1.00K | $2.31M | $-16.00K | $-45.20M | $-42.89M | (m) | 12 month · $1.92M | (m) |
| 2021-09-30 | (m) | $27.00K | $232.53M | $-2.00K | $-133.18M | $99.37M | (m) | 3 month · $1.00M | (m) |
| 2021-06-30 | (m) | $19.00K | $184.48M | (m) | $-119.53M | $64.97M | (m) | 3 month · $917.00K | (m) |
| 2021-03-31 | (m) | $18.00K | $181.94M | $1.00K | $-106.37M | $75.59M | (m) | 3 month · $947.00K | (m) |
| 2020-12-31 | (m) | $18.00K | $180.53M | $4.00K | $-96.11M | $-20.30M | (m) | 12 month · $2.23M | 12 month · $7.86M |
| 2020-09-30 | (m) | $18.00K | $179.25M | $24.00K | $-84.59M | $94.70M | (m) | 3 month · $642.00K | (m) |
| 2020-06-30 | (m) | $18.00K | $178.40M | $48.00K | $-72.17M | $106.30M | (m) | 3 month · $550.00K | (m) |
| 2020-03-31 | (m) | $17.00K | $167.16M | $-16.00K | $-61.97M | $105.19M | 3 month · $20.00K | 3 month · $360.00K | 3 month · $7.86M |
| 2019-12-31 | (m) | $1.00K | $5.87M | $32.00K | $-54.75M | $-48.85M | (m) | 12 month · $899.00K | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | $-41.90M | (m) | 3 month · $310.00K | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | $-35.62M | (m) | 3 month · $197.00K | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | $-30.41M | (m) | 3 month · $95.00K | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $-26.32M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |